It’s All About Delivery: Pre-Clinical Development of a Surfactant Powder Aerosol Product

M Hindle; DR Farkas; RM DiBlasi; M Momin; H KenKnight; F Hall; CJ Dalton; Q Xu; Rudra Pangeni; G Aladwani; S Strickler; P Longest

It’s All About Delivery: Pre-Clinical Development of a Surfactant Powder Aerosol Product

M Hindle
, DR Farkas
, RM DiBlasi
, M Momin
, H KenKnight
, F Hall
, CJ Dalton
, Q Xu
, Rudra Pangeni
, G Aladwani
, S Strickler
, P Longest

Department of Pharmaceutical Sciences

Research output: Contribution to journal › Meeting abstract

Abstract

Neonatal Respiratory Distress Syndrome (RDS) remains a leading cause of infant morbidity and mortality, particularly in preterm infants who lack sufficient pulmonary surfactant. Current treatment involves invasive administration of animal-derived liquid surfactant, which, despite being lifesaving, carries significant risks and is often inaccessible in low-resource settings. This work presents the development of a novel dry powder surfactant aerosol designed for non-invasive delivery, targeting the alveolar region with high efficiency and minimal equipment. The lead formulation, composed of synthetic phospholipids, is engineered for delivery via a low-flow air-jet inhaler suitable for fragile neonatal lungs. Pharmaceutical stability, dispersibility, and in vivo performance data support the feasibility of this approach as a transformative solution for global neonatal care.

Original language	American English
Pages (from-to)	1-7
Journal	Respiratory Drug Delivery
Volume	1
State	Published - 2025

Access to Document

https://rddonline.com/rdd/article.php?id=0&sid=103&ArticleID=3144&return=1

Cite this

@article{d538b561050e4d198180c3547c69f071,

title = "It{\textquoteright}s All About Delivery: Pre-Clinical Development of a Surfactant Powder Aerosol Product",

abstract = "Neonatal Respiratory Distress Syndrome (RDS) remains a leading cause of infant morbidity and mortality, particularly in preterm infants who lack sufficient pulmonary surfactant. Current treatment involves invasive administration of animal-derived liquid surfactant, which, despite being lifesaving, carries significant risks and is often inaccessible in low-resource settings. This work presents the development of a novel dry powder surfactant aerosol designed for non-invasive delivery, targeting the alveolar region with high efficiency and minimal equipment. The lead formulation, composed of synthetic phospholipids, is engineered for delivery via a low-flow air-jet inhaler suitable for fragile neonatal lungs. Pharmaceutical stability, dispersibility, and in vivo performance data support the feasibility of this approach as a transformative solution for global neonatal care.",

author = "M Hindle and DR Farkas and RM DiBlasi and M Momin and H KenKnight and F Hall and CJ Dalton and Q Xu and Rudra Pangeni and G Aladwani and S Strickler and P Longest",

year = "2025",

language = "American English",

volume = "1",

pages = "1--7",

journal = "Respiratory Drug Delivery",

}

TY - JOUR

T1 - It’s All About Delivery: Pre-Clinical Development of a Surfactant Powder Aerosol Product

AU - Hindle, M

AU - Farkas, DR

AU - DiBlasi, RM

AU - Momin, M

AU - KenKnight, H

AU - Hall, F

AU - Dalton, CJ

AU - Xu, Q

AU - Pangeni, Rudra

AU - Aladwani, G

AU - Strickler, S

AU - Longest, P

PY - 2025

Y1 - 2025

N2 - Neonatal Respiratory Distress Syndrome (RDS) remains a leading cause of infant morbidity and mortality, particularly in preterm infants who lack sufficient pulmonary surfactant. Current treatment involves invasive administration of animal-derived liquid surfactant, which, despite being lifesaving, carries significant risks and is often inaccessible in low-resource settings. This work presents the development of a novel dry powder surfactant aerosol designed for non-invasive delivery, targeting the alveolar region with high efficiency and minimal equipment. The lead formulation, composed of synthetic phospholipids, is engineered for delivery via a low-flow air-jet inhaler suitable for fragile neonatal lungs. Pharmaceutical stability, dispersibility, and in vivo performance data support the feasibility of this approach as a transformative solution for global neonatal care.

AB - Neonatal Respiratory Distress Syndrome (RDS) remains a leading cause of infant morbidity and mortality, particularly in preterm infants who lack sufficient pulmonary surfactant. Current treatment involves invasive administration of animal-derived liquid surfactant, which, despite being lifesaving, carries significant risks and is often inaccessible in low-resource settings. This work presents the development of a novel dry powder surfactant aerosol designed for non-invasive delivery, targeting the alveolar region with high efficiency and minimal equipment. The lead formulation, composed of synthetic phospholipids, is engineered for delivery via a low-flow air-jet inhaler suitable for fragile neonatal lungs. Pharmaceutical stability, dispersibility, and in vivo performance data support the feasibility of this approach as a transformative solution for global neonatal care.

M3 - Meeting abstract

VL - 1

SP - 1

EP - 7

JO - Respiratory Drug Delivery

JF - Respiratory Drug Delivery

ER -